CDRI 97/78

Drug Profile

CDRI 97/78

Alternative Names: 97/78; CDRI-97/78; CDRI-9778; Compound 97/78

Latest Information Update: 11 Mar 2016

Price : $50

At a glance

  • Originator Central Drug Research Institute
  • Developer Central Drug Research Institute; Ipca Laboratories
  • Class Antimalarials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Malaria

Most Recent Events

  • 31 Dec 2006 Compound 97/78 is still in Preclinical trials for Malaria in India
  • 30 Nov 2004 Preclinical trials in Malaria in India (Parenteral)
  • 30 Nov 2004 Preclinical trials in Malaria in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top